Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2025-03-25 Report Publication Anno…
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
Report Publication Announcement Classification · 98% confidence The document is a press release titled "Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F". It explicitly states that the company has filed its 2024 Universal Registration Document (URD) and Form 20-F with regulatory bodies (AMF and SEC). The URD includes the Annual Financial Report, Annual Management Report, Corporate Governance Report, and Sustainability Statement. Since the document itself is an announcement about the *filing* of these comprehensive reports, and given its short length (2835 characters), it fits the definition of a Report Publication Announcement (RPA) rather than being the full 10-K or AR itself. The key indicator is the phrase 'Announces Filing of...'.
2025-03-25 English
Valneva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son rapport annuel américain « Form 20-F »
Report Publication Announcement Classification · 98% confidence The document is a press release from Valneva SE dated March 25, 2025. The headline explicitly states: "Valneva annonce le dépôt de son Document d'Enregistrement Universel 2024 et de son rapport annuel américain « Form 20-F »" (Valneva announces the filing of its 2024 Universal Registration Document and its US annual report "Form 20-F"). 1. The 'Document d'enregistrement universel 2024' (Universal Registration Document) contains the 'rapport financier annuel 2024' (2024 annual financial report), management report, governance report, and sustainability report. This comprehensive annual filing structure strongly suggests the content is related to the Annual Report (10-K equivalent for European filers, though the URD is distinct, it serves the same primary annual reporting function). 2. The mention of filing the 'Form 20-F' with the SEC confirms this is the company's primary annual disclosure document for US markets. 3. However, the document itself is an *announcement* stating that these reports *have been filed* ('a annoncé aujourd'hui le dépôt'). It is not the full 10-K or URD itself, but a notice about their publication. 4. According to Rule 2 ('MENU VS MEAL' RULE): If a document is short and states a report 'has been published' or 'has been filed', it should be classified as a Report Publication Announcement (RPA). 5. The document length is 3274 characters, which is short, supporting the RPA classification over the full report classification (10-K). 6. Therefore, the most accurate classification is RPA, as it announces the publication of the annual reports (URD and 20-F).
2025-03-25 French
20-F
Annual Report FY 2024
2025-03-24 English
6-K
Regulatory Filings
2025-03-24 English
Document d'enregistrement universel 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-03-24 French
Valneva répond à l'appel du gouvernement français pour la fourniture du vaccin IXCHIQ® contre l'épidémie de chikungunya à La Réunion
Regulatory Filings Classification · 100% confidence The document is a press release dated March 24, 2025, announcing that Valneva is responding to a request from the French government to supply 40,000 doses of its IXCHIQ® vaccine against the chikungunya epidemic in La Réunion. It details the supply agreement, public health context, and mentions regulatory approvals and partnerships (CEPI, SII, Butantan). This type of announcement, which communicates a specific business/operational event (a supply contract/response to a public health need) rather than routine financial results (ER/IR) or mandatory regulatory filings (10-K/DEF 14A), fits best under a general announcement category. Since it is not a formal financial report, a management discussion, a proxy statement, or a specific capital change, it is classified as a general Regulatory Filing (RNS) as it is a public announcement of a significant operational event, or potentially an Earnings Release (ER) if it were tied to quarterly results, but here it is clearly a specific operational/supply announcement. Given the options, RNS serves as the best general regulatory/public announcement fallback for non-standard corporate news that is not explicitly covered by other codes like DIV, CAP, or MANG. It is not an Earnings Release (ER) as it focuses on supply logistics, not financial performance highlights. It is not an RPA because it is the content of the announcement itself, not just an announcement *about* another report.
2025-03-24 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.